The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shandong Hanfang Pharmaceutical Co., Ltd. 山東漢方製藥股份有限公司 (A joint stock company incorporated in the People's Republic ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Zhejiang Jingxin Pharmaceutical Co., Ltd. 浙 江 京 新 藥 業 股 份 有 限 公 司 (A joint stock company incorporated in the People's Republic of China with limit ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Shandong Hanfang Pharmaceutical Co., Ltd. 山東漢方製藥股份有限公司 No offer or invitation will be made to the public in Hong Kong until after a prospectus of ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. ...

STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. On February 6, 2026, it was announced that KDventures and the other shareholders of SVF Vaccines had entered into an acquisition agreement with Novakand Pharma regarding a reverse acquisition of SVF Vaccines. Comple ...

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance. 7 Best Dialysis and Kidney Disease Stocks to Buy yezry/Shutterstock.com Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lea ...

Core Insights - Analysts project Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.42 per share, reflecting a 40% decline year over year [1] - Revenue estimates for the quarter are set at $140.02 million, indicating a 1.3% decrease from the same period last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, suggesting stability in analysts' forecasts [1] Revenue Projections - Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to be $96.43 million, representing a year-over-year increase of 16.9% [4] - The consensus for 'Revenues- Product revenue, Net- FYCOMPA' is $12.28 million, indicating a significant decline of 67.9% year over year [4] - For 'Revenues- Product revenue, Net- AGAMREE', analysts project $31.30 million, reflecting a year-over-year increase of 48.5% [4] Overall Performance - The average prediction for 'Revenues- Product revenue, net' stands at $140.01 million, showing a year-over-year change of -1.3% [5] - Over the past month, Catalyst shares have gained 0.5%, while the Zacks S&P 500 composite has decreased by 1% [5] - Catalyst holds a Zacks Rank of 3 (Hold), suggesting its performance is expected to align with the overall market in the near term [5]

In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 58.7% compared to the same period last year. Revenues are forecasted to be $379.96 million, representing a year-over-year decrease of 11.6%.The consensus EPS estimate for the quarter has been revised 152.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

Pfizer (NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4% dividend yield. For reference, the average pharma stock has a yield of just 1.7%. There's a reason to buy Pfizer beyond the yield. Pfizer gets you most of the way to 10% If you buy Pfizer and collect that 6.4% dividend yield, you are roughly two-thirds of the way toward the 10% return that most investors expec ...

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsGeoff Meacham - Managing DirectorJohn Paolini - Chief Medical OfficerJonathan Kirshenbaum - Senior Manager of Investor RelationsMark Ragosa - CFONick Lorusso - VP of Biotech Equity ResearchRoss Moat - COOSanj Patel - CEOConference Call ParticipantsEva Fortea - Executive Director and Senior Biotechnology AnalystJoysree Zanfir - AnalystRoger Song - Senior Equity Research AnalystOperato ...